Delenex Therapeutics AG, a Zürich-Schlieren, Switzerland-based biotech company developing therapeutic antibody fragments targeting serious medical diseases, has closed its CHF13.5m (approximately US$14m, €10m) Series A venture capital financing round.
The round was led by SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners.
Delenex Therapeutics intends to use the funding to develop therapeutic antibody fragments for central nervous system (CNS), inflammatory, respiratory and dermatologic disorders. The company plans to initiate additional clinical trials within the near future.
Spun out of ESBATech AG in September 2009, Delenex has received access to all rights to the further development, application and royalty-free commercialisation of the clinically validated ESBATech antibody technology and products in all fields outside ophthalmology.
The company’s management team includes Thomas Hecht MD (Executive Chairman), Titus Kretzschmar PhD (Chief Scientific Officer) and Hamish Cameron MD (Business Development).